Literature DB >> 2840832

So-called sclerosing hemangiomas of lung. An immunohistochemical study supporting a respiratory epithelial origin.

S A Yousem1, M R Wick, G Singh, S L Katyal, J C Manivel, S E Mills, J Legier.   

Abstract

Sclerosing hemangiomas are benign pulmonary neoplasms. They were initially believed by Liebow and Hubbell to be of endothelial origin; however, subsequent ultrastructural studies have suggested an alveolar pneumocyte and mesothelial derivation. Using a panel of various antibodies on eight cases, the authors found that sclerosing hemangiomas expressed cytokeratin (seven cases), epithelial membrane antigen (seven cases), carcinoembryonic antigen (five cases), vimentin (seven cases), surfactant apoprotein (eight cases), and Clara cell antigen (five cases). These results support the hypothesis that sclerosing hemangiomas represent an epithelial tumor showing simultaneous bronchiolar epithelial and alveolar pneumocyte differentiation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2840832

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  4 in total

1.  SCLEROSING HAEMANGIOMA OF LUNG PRESENTING AS SPONTANEOUS HAEMOTHORAX.

Authors:  S C Tewari; P Shrikhande; A K Rajput; J M Borcar; K Chand
Journal:  Med J Armed Forces India       Date:  2011-07-21

2.  Monoclonality of both pale cells and cuboidal cells of sclerosing hemangioma of the lung.

Authors:  S Niho; K Suzuki; T Yokose; T Kodama; Y Nishiwaki; H Esumi
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

Review 3.  Imaging of macrophage-related lung diseases.

Authors:  Katharina Marten; David M Hansell
Journal:  Eur Radiol       Date:  2005-01-05       Impact factor: 5.315

4.  Type-II pneumocyte differentiation in pulmonary sclerosing hemangioma: ultrastructural differentiation and immunohistochemical distribution of lineage-specific transcription factors (TTF-1, HNF-3 alpha, and HNF-3 beta) and surfactant proteins.

Authors:  Kazuto Yamazaki
Journal:  Virchows Arch       Date:  2004-05-11       Impact factor: 4.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.